Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACWY-TT booster immunogenicity study in adolescents previously primed with MenC vaccine
2013-004778-84Phase 3Terminated
- Sponsor
- GSK
- Start
- Jan 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of Meningococcal polysaccharide vaccine group W-135 in meningococcal disease (2 arms), sponsored by GSK. Primary endpoint: Immunogenicity with respect to the components of the investigational vaccine. Started Jan 2014; status: terminated.
02
Drugs
Meningococcal polysaccharide vaccine group W-135
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2013-004778-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004778-84.